Recently, the results of the “High-Integrity Enterprises” Selection and Publicity Campaign in Sichuan Province were announced, which was jointly organized by 25 departments such as Sichuan Provincial Development and Reform Commission, Cyberspace Administration Office of Sichuan Provincial Party Committee, and State-owned Assets Supervision and Administration Commission of Sichuan Province. Chengdu Olymvax Biopharmaceuticals Inc. won the title of “High-Integrity Enterprises in Sichuan Province” in 2021.

This Selection and Publicity Campaign aimed to fully implement the spirit of the 19^th CPC National Congress and the Fifth Plenary Session of the 19^th CPC Central Committee, further practice the socialist core values, create a good social ethos of honesty and trustworthiness, comprehensively demonstrate the features of high-integrity enterprises in Sichuan Province, actively guide enterprises to constantly regulate their credit behaviors, improve credit ability, accumulate credit value, create credit brands, assume social responsibility, and jointly create a social atmosphere of “learning, knowing, managing and using credit”. After online registration, preliminary review, online voting, expert review and other procedures, the list of “High-Integrity Enterprises in Sichuan Province” in 2021 was finalized.

OLYMVAX always insists on operating in good faith according to the law, actively fulfills its social responsibilities, and has no bad credit records since its establishment. In terms of honest production, Tetanus Vaccine, Adsorbed of the Company has been rated as the “Most Influential Honest Product” in Sichuan Province.

OLYMVAX was successfully nominated for the High-Integrity Enterprises in Sichuan Province, proving its high integrity. In the future, OLYMVAX will adhere to the business philosophy of “strengthening process management, focusing on continuous improvement, and pursuing the highest quality”, continuously provide high-quality vaccines to customers to help them keep a good health state, promote the sustainable development of the biomedical industry, and eventually grow into a “domestically leading and internationally renowned” vaccine supplier.